A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease

NCT01603069 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson's Disease

Interventions

DRUG: AZD3241 300 mg BID
DRUG: AZD3241 600 mg BID
DRUG: Placebo

Sponsor

AstraZeneca